EN | RU
EN | RU

Help Support

Back

Famciclovir + celecoxib: A safe and effective combination for fibromyalgia treatment

Famciclovir + celecoxib: A safe and effective combination for fibromyalgia treatment Famciclovir + celecoxib: A safe and effective combination for fibromyalgia treatment
Famciclovir + celecoxib: A safe and effective combination for fibromyalgia treatment Famciclovir + celecoxib: A safe and effective combination for fibromyalgia treatment

What's new?

Famciclovir and celecoxib acts act additively and/or synergistically to treat various symptoms of fibromyalgia explaining a persistent nociceptive infection with HSV may lead to this chronic pain syndrome in some patients. 

Fibromyalgia is a disorder identified by musculoskeletal pain, fatigue, sleep, memory and mood issues. The development of fibromyalgia has been implicated by infections and other stressors. These stressors could result in repeated reactivations of latent herpes virus infections, leading to the development of fibromyalgia. This study evaluated a new drug combination famciclovir + celecoxib (IMC-1) active against suspected herpes virus reactivation and infection, hence, used for cure of fibromyalgia.

A trial was conducted with 143 fibromyalgia patients enrolled at 12 sites in a 16-week, double-blinded, placebo-controlled proof-of-concept. These randomized patients received either IMC-1 or placebo in a 1:1 ratio. The results were supported by parameters, 24-hour recall pain Numerical Rating Scale, the Revised Fibromyalgia Impact Questionnaire (FIQ-R), Patient’s Global Impression of Change (PGIC) questionnaire, Multidimensional Fatigue Inventory, NIH Patient-Reported Outcomes Measurement Information System (PROMIS) and the Beck Depression Inventory-II studied at baseline and 6, 12, 16 weeks.  

The results indicated that there is a significant decrease in fibromyalgia-related pain in patients on IMC-1 treatment versus placebo. IMC-1 treatment significantly improved PGIC response rates. Patient self-reported functioning was measured by the FIQ-R and found to be improved. Fatigue was found to be significantly improved as measured by the PROMIS fatigue inventory. The safety profile was quite stimulating.  Adverse events were reported less frequently in the IMC-1 group when Gastrointestinal and nervous system treatment was done despite the celecoxib component of IMC-1. 

Study of results proved that IMC-1 was efficacious and safe in treating symptoms of fibromyalgia, which supports the hypothesis that herpes virus infections can also contribute to this syndrome. The safety and efficacy of above combination was suggested by improved retention rates, decreased adverse event rates and evidence of efficacy on a broad spectrum of outcome measures.  

Source:

Dove press

Article:

A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia

Authors:

Pridgen WL et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: